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Abstract
Background: The Indian guidelines on following up sputum smear-negative Pulmonary tuberculosis (PTB) patients differ
from the current World Health Organization (WHO) guidelines in that the former recommends two follow up sputum
examinations (once at the end of intensive phase and the other at the end of treatment) while the latter recommends only
one follow up sputum smear microscopy examination, which is done at the end of the intensive phase. This study was
conducted to examine if there was any added value in performing an additional sputum smear examination at the end of
treatment within the context of a national TB program.
Methods: This study was a descriptive record based review conducted in nine tuberculosis (TB) units in Delhi, India. All
consecutive new sputum smear-negative PTB patients registered in these nine TB units from 1
st January 2009 to 31
st
December 2009 were included in the study.
Results: Of 2567 new sputum smear-negative TB patients, 1973 (90%) had sputum specimens examined at the end of the
intensive phase, of whom 36 (2%) were smear-positive: the majority (n=28) successfully completed treatment with either
the same or a re-treatment regimen. At treatment completion, 1766 (85%) patients had sputum specimens examined, of
whom 16 (0.9%) were smear-positive: all these were changed to a re-treatment regimen. Amongst the sputum-positive
patients identified as a result of follow up (n=52), four were diagnosed with multi-drug resistant TB (MDR-TB), three of
whom were detected after smear examination at the end of treatment.
Conclusions: Given the high burden of TB in India, a 0.9% additional yield of smear-positive sputum smears at the end of
treatment translates to 3,297 cases of smear-positive PTB. End-of-treatment smear is a low-yield strategy for detection of
smear-positive TB cases, although further studies are needed to determine its population-level impact and cost, particularly
in relation to other TB control interventions.
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Introduction
India is the highest tuberculosis (TB) burden country in the
world accounting for one fifth of global incidence [1]. In 2009, 1.5
million patients were placed on anti-TB treatment in India, of
whom 366,381 (24%) were registered as new sputum smear-
negative pulmonary TB cases [2].
According to current Indian guidelines, a patient is labelled as
sputum smear-negative pulmonary tuberculosis (PTB) when he/
she has clinical features of PTB, has two consecutive sputum smear
examinations negative for acid-fast bacilli (AFB) and has
radiographic abnormalities consistent with active PTB, as deter-
mined by a medical officer [3]. A patient whose sputum smears are
negative for AFB but who has Mycobacterium tuberculosis identified
on culture is also designated as sputum smear negative PTB. Such
patients who are placed on treatment have follow up sputum
smear examinations performed twice during the entire course of
anti-TB treatment. This includes a first follow-up smear at the end
of the intensive phase of treatment (2 months) and a second smear
at the end of treatment (6 months) [3]. The purpose of these follow
up smear examinations is to assess the response to therapy, check
on whether there has been a misdiagnosis, and to determine if
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resistance. All these factors could result in an initially smear-
negative PTB patient becoming smear-positive at the end of the
intensive phase or on completion of treatment.
The Indian guidelines on following up sputum smear-negative
PTB patients differ from the current World Health Organization
(WHO) guidelines in that the latter recommends only one follow
up sputum microscopy examination, which is done at the end of
the intensive phase [4].This made us to ask; is there added value in
performing an additional sputum smear examination at the end of
treatment within the context of a national TB program?
In a cohort of newly registered sputum smear-negative PTB
patients, we determined i) the proportion of patients who had
sputum smear examinations done at the end of the intensive phase
and at the end of treatment, ii) the number and percentage of
patients with positive sputum smears at these time points and iii)
the treatment outcomes of those patients who were found to be
sputum smear-positive.
Materials and Methods
Design
This was a descriptive study using routine programme data.
Study setting
The study was conducted in the state of Delhi, the National
Capital of India. Delhi has an area of 1483 sq km, with a total
population of 17 million and population density of 11,000/sq km,
with 40% of the population living in slums or similar contexts. The
Revised National TB Control Programme (RNTCP) has been
implemented in all districts of Delhi since 1997. For the
management of RNTCP, the state has been divided into 24
Chest Clinics [5]. Under each Chest Clinic, there is one
Tuberculosis Unit (TU) for half a million population having a
Designated Microscopy Centre for every 0.1 million population.
The 24 Chest Clinics under RNTCP fall within the nine Revenue
Districts of Delhi State.
Patients were registered in the programme in one of three
treatment categories: details of these categories and the treatment
regimens are presented in Table 1. At the end of treatment, one
of several mutually exclusive treatment outcomes is given to
patients as shown in Table 2. Most of the new sputum smear-
negative pulmonary TB patients were treated with a category 3
regimen, but some with serious illness were treated with a category
1 regimen. The patients were treated using the Directly Observed
Treatment Short course (DOTS) approach, and were supervised
regularly thrice a week in the intensive phase and once a week
during the continuation phase. They were followed with sputum
smear examination at the end of the intensive phase (2 months)
and on treatment completion (6 months) [3]. Sputum smears were
examined in quality assured laboratories and results were recorded
in the TB register. If patients failed on treatment (i.e., were found
to be sputum smear positive at 5 months or later), they were
changed to a retreatment category 2 regimen. Such patients were
also considered to be suspects of MDR-TB (Multi-Drug Resistant
TB-resistant to rifampicin and isoniazid) and their sputum
specimens were sent to an accredited laboratory facility for culture
and drug sensitivity testing.
Study population
From each of the nine revenue districts of Delhi, if there were
more than one tuberculosis units, the TB unit that registered the
maximum number of patients during the study period was selected
for inclusion in the study. All consecutive new sputum smear-
negative pulmonary TB patients registered in these nine TB units
from 1
st January 2009 to 31
st December 2009 were included in the
study.
Data collection and analysis
Data were obtained from the TB registers. A data extraction
sheet was used by the study investigators to capture details on
sputum smear examination and treatment outcome status at the
end of the intensive phase and on treatment completion. Cross
validation of the records was undertaken for 10% of smear-
negative Pulmonary TB patients by examining patient treatment
cards and TB Laboratory registers. Data were entered and
analyzed using a Microsoft Excel spreadsheet Version 2007.
Ethics approval
Ethical approval was obtained from the Institutional Ethics
Committee of Public Health Foundation of India, New Delhi and
the Union Ethics Advisory Group, Paris. The study was a
retrospective review of routine programme records and reports,
and permission was obtained from the programme managers at
the state and national levels to access these data. Individual patient
consent was deemed un-necessary by both the ethics committees.
Electronic databases created for the analysis were stripped of
personal health identifiers and maintained securely.
Results
Sputum examinations during and at end of treatment
A total of 2,567 new sputum smear negative PTB patients were
registered in the 9 TB units in Delhi. The management of these
patients and the numbers who were eligible for and had sputum
smear examination performed from diagnosis until the end of
treatment is shown in Figure 1.
Smear status at the end of the Intensive phase of anti-
tuberculosis treatment
Of all newly registered patients, 367 (14%) were not eligible for
sputum smear examination at end of the intensive phase due to
various reasons shown in Figure 1, Of those eligible for sputum
smear examination at this point, 227 (10%) failed to have the
examination. There were 1973 patients whose sputum smears
were examined, of whom 36 (2%) were sputum smear-positive. Of
the latter, 25 were receiving category 1 treatment and 11 receiving
category 3 treatment. The treatment outcomes of patients who
were smear-positive at the end of the intensive phase are shown in
Figure 2. Amongst the category 1 patients who were found to be
smear-positive (25), all continued their same treatment regimens
and the majority successfully completed treatment. There were
two patients who were changed to a retreatment category 2
regimen, of whom one was later diagnosed with multi-drug
resistant TB (MDR-TB, i.e., TB resistant to both isoniazid and
rifampicin) and switched over to category 4 treatment for its
management. Of the patients who were receiving category 3
treatments and were smear-positive at the end of the intensive
phase (11), all were changed to a re-treatment category 2 regimen.
The majority of these patients had a successful treatment outcome.
Smear status at the end of anti-tuberculosis treatment
During the continuation phase of treatment, 111 (5%) patients
were not eligible for sputum smear examination at the end of
treatment (6 months) due to various reasons shown in Figure 1.
Of those eligible for sputum smear examination, 323 (15%) did not
have the examination done. There were 1766 patients whose
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16 (0.9%) were sputum smear-positive.
Amongst these smear-positive patients, 6 were receiving
category 1 and 10 were receiving category 3 treatment regimens.
Of the 16 smear-positive patients, 12 were changed to a category 2
retreatment regimen. Two other patients from each category were
lost to follow up after their treatment was completed and their
outcome was registered as treatment completed. The outcomes of
the 12 patients who were changed to a retreatment regimens
shown in Figure 3. Three of these 12 patients were later
diagnosed with MDR-TB and were switched to a MDR-TB
treatment regimen for its management.
Sensitivity analysis and costs for sputum smear at end of
anti-tuberculosis treatment
A sensitivity analysis was performed to check what the estimate
would have been if all of the patients who did not get their last
follow up sputum smear examination turned out to be smear-
positive or smear-negative. If all the missing patients had been
smear-positive, the smear-positivity rate at the end of treatment
would have been 16%. Conversely, if all these patients had been
smear-negative, then the estimate would have been 0.8%. Even
with the low estimate of 0.8%, from a public health perspective,
the absolute number in terms of cases of potentially resistant TB
cases identified is still significant.
Table 1. Treatment categories and regimens under Revised National TB programme, India.
Treatment category Type of patients Treatment regimens***
Intensive Phase Continuation phase
Category 1 New sputum smear-positive PTB 2(H3R3Z3E3)4 ( H 3R3)
New sputum smear-negative PTB, seriously ill*
New extra-PTB, seriously ill*
Category 2 Sputum smear-positive relapse 2(H3R3Z3E3S3)+1(H3R3Z3E3)5 ( H 3R3E3)
Sputum smear-positive treatment failure
Sputum smear-positive treatment after default
Category 3 New sputum smear-negative, not seriously ill** 2(H3R3Z3)4 ( H 3R3)
New extra-PTB, not seriously ill**
Category 4 Multi Drug Resistant –TB (MDR-TB)**** 6 (9) Km Lvx Eto Cs Z E (daily) 18 Lvx Eto Cs E (daily)
PTB=Pulmonary Tuberculosis; EPTB=Extrapulmonary Tuberculosis; H=Isoniazid; R=Rifampicin; Z=Pyrazinamide; E=Ethambutol; Km=Kanamicin; Lvx=Levofloxacin;
Eto=Ethionamide; Cs=Cycloserine.
The number before the letters indicates number of months of treatment; numbers in subscript indicate the number of days per week of doses.
*Seriously ill includes patients that have military TB, extensive parenchymal infiltration, co-infection with HIV, cavitary disease. In children, seriously ill sputum smear-
negative PTB includes all forms of sputum smear-negative PTB other than primary complex. Seriously ill EP-TB includes TB meningitis (TBM), disseminated TB, TB
pericarditis, TB peritonitis and intestinal TB, bilateral extensive pleurisy, spinal TB with or without neurological complications, genitourinary TB, and bone and joint TB.
**Not seriously ill sputum smear-negative PTB includes primary complex. Not seriously ill EP-TB includes lymph node TB and unilateral pleural effusion.
***The dosage strengths are as follows: H : Isoniazid (600 mg), R:Rifampicin (450 mg), Z: Pyrazinamide (1500 mg); E: Ethambutol (1200 mg); S: Streptomycin (750 mg).
****MDR-TB diagnosis is done through culture and drug sensitivity testing from a quality-assured laboratory. Treatment of MDR-TB uses a standardized regimen,
comprising of 6 drugs – Km (Kanamycin), Lvx (levofloxacin), Eto (Ethionamide), Z (pyrazinamide), E (Ethambutol) and Cs (Cycloserine) during 6–9 months of intensive
phase and 4 drugs (Lvx, Eto, E and Cs) during the 18 months of continuation phase. Dosages of drugs are based on three weight bands (16–25 kg, 26–45 Kg, and
.45 Kg).
doi:10.1371/journal.pone.0049238.t001
Table 2. Definitions of treatment outcomes.
Outcome: Definition
Cured: A patient who is initially sputum smear-positive, who has completed treatment and has negative sputum smears, on two occasions, one of which was at the
end of treatment.
Treatment completed: A patient who is sputum smear-positive who has completed treatment, with negative smears at the end of the intensive phase but none at
the end of treatment.
Or: A sputum smear-negative TB patient who has received a full course of treatment and has not become smear-positive during or at the end of treatment.
Or: An extra-pulmonary TB patient who has received a full course of treatment and has not become smear-positive during or at the end of treatment.
Treatment success: Includes cured and treatment completed together
Death: A patient who died during the course of treatment regardless of cause
Failure: A TB patient who is smear positive at 5 months or more after starting treatment. Failure also includes a patient who was treated with Category III regimen but
who becomes smear positive during treatment. And the patient is not put on MDR-TB treatment
Defaulted: A patient who has not taken anti-TB drugs for 2 or more consecutive months after starting treatment.
Transferred out: A patient who has been transferred to another Tuberculosis Unit/District and his/her treatment outcome is not known
Switched over to MDR-TB treatment: A patient who has been diagnosed as having MDR-TB by an RNTCP accredited laboratory, prior to being declared as ‘‘Failure’’,
and is placed on the RNTCP MDR-TB treatment regimen
doi:10.1371/journal.pone.0049238.t002
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our setting is US $ 0.90 [6]. In this study, 1766 patients at the end
underwent sputum examination with 15 patients experiencing a
change in either treatment category, yielding a Cost Benefit Ratio
(CBR) of US $ 106/ treatment regimen changed. If all eligible
patients in the study cohort (2089) had undergone the last sputum
smear examination and all the missing patients were smear
positive resulting in a change in treatment regimen, the CBR
would have been US $ 5/ treatment regimen changed. On the
other hand, if all the missing patients were smear-negative, CBR
would have been US $ 125/ treatment regimen changed.
Discussion
This is one of the first studies evaluating the added value of
sputum smear examinations at the end of the intensive as well as
the end of treatment in new sputum smear negative PTB patients.
The majority of patients who were eligible to submit sputum
specimens at the end of the intensive phase of treatment and at the
end of treatment had their sputum smears examined. Smear-
positivity was 2% for the smear examination at the end of the
intensive phase and 0.9% at the end of treatment. These
percentages may seem low, but in India with an estimated
366,381 annual new smear negative PTB patients registered in
2009, this translates to over 7000 cases with positive smears at 2
months and 3297 cases of smear positive PTB at the end of
treatment. For patients on the category 3 regimen, all of those with
smear-positive sputum at 2 months were changed to a retreatment
regimen with a generally successful treatment outcome, so action
was taken on the result. Action was not so clear for those found to
be smear-positive at the end of treatment. A quarter of patients
were incorrectly registered as treatment completed. The remain-
der was changed to a re-treatment regimen with mixed results, but
Figure 1. Flow Chart showing sputum smear examination at end of intensive phase and end of treatment in new smear negative
pulmonary tuberculosis patients in Delhi, India (2009).
doi:10.1371/journal.pone.0049238.g001
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appropriate treatment, an action which would not have occurred if
the smear examination had not been performed.
There are important public health implications from these
findings. First, persistent smear positivity at the end of treatment
completion might herald misdiagnosis, failure on current drug
regimens or primary or acquired drug resistance. In particular, the
possibility of persistent smear positivity heralding MDR-TB is of
major concern as this form of drug resistance needs early
identification in order to limit its spread to households and the
community at large. Such cases will add to the ‘‘difficult to
manage’’ TB cases and the already high background burden of
disease. Second, from a patient perspective, this failure of
treatment is likely to impact on individual survival. It is not
known what happened to the patients with smear-positive sputum
at the end of treatment who were incorrectly declared successfully
treated or what happens in general to these patients if the smear
examination is not performed. However, it is likely that outcomes
are compromised.
One consideration is that our study group included patients in
category 3 with a three-drug treatment regimen in the intensive
phase in addition to patients in category 1 who were treated with a
Figure 2. Final treatment outcomes in patients who were smear-positive at the end of the intensive phase of anti-tuberculosis
treatment.
doi:10.1371/journal.pone.0049238.g002
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3 regimen is considered a relatively inferior regimen and no longer
exists in the country. It is possible that the country-wide shift to a
category 1 regimen for all smear-negative PTB patients might
affect our study estimate of 1%. It is thus urgent that RNTCP
audits current data under the revised national guidelines to fully
validate these findings.
The strengths of this study are that a large number of patients
were studied, and we used routine programme data. The findings
are therefore likely to reflect the operational reality on the ground.
We have also adhered to the STROBE guidelines on reporting
[7].
The study has a number of limitations. First, the use of record
reviews does mean that sometimes the data are inaccurately
recorded. Second, our estimate of the added value of 0.9% positive
sputum smears at the end of treatment might be affected by the
15% of patients who for various reasons did not undergo the last
follow up smear examination at the end of treatment completion.
A large number of patients not undergoing follow-up sputum
smear examination is not unique to this study and/or region and
has also been highlighted in another study from a different region
in the country [8]. Even with a low estimate of 0.8%, obtained
through the sensitivity analysis presented in the results, from a
public health perspective, the absolute number in terms of cases of
potentially resistant TB cases identified is still significant. Third,
sputum smear microscopy as a tool of diagnosis is challenged by
the issue of false positive and false negative results, which may
occur even within quality assured programmes. However, sputum
smear microscopy is the mainstay of diagnosis programmatically in
India, and is used to identify patients who may be at risk of drug-
resistant disease during follow up and who may need additional
culture and drug sensitivity testing. Finally, we were unable to
ascertain the number of patients who were sputum smear positive
in follow up smears and were concomitantly HIV-seropositive as
during the study period HIV testing was not routinely performed.
This is the first report of its kind coming from a high TB burden
country like India, but like many studies it raises additional
questions. First, the RNTCP has stopped giving category 3
treatment, and therefore a similar study with the same research
question should be conducted for another cohort of patients
Figure 3. Final treatment outcomes in patients who were smear-positive at the end of anti-tuberculosis treatment.
doi:10.1371/journal.pone.0049238.g003
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study should be done for a similar cohort of patients as this would
obviate a number of the limitations inherent in this retrospective
record review study. A prospective study could also include
sputum culture and drug sensitivity testing on all specimens as well
as a detailed cost-analysis on all aspects. The decision to continue
sputum smear examination at end of continuation phase will also
be dependent on CBR of the additional sputum smear examina-
tion. Given the political commitment by the Government of India
to support the RNTCP with the aim of improving its performance
over several years, the current costs of performing the additional
end-of-treatment smear as presented in the results section, do not
seem to impose an economic challenge to the programme. The
end of smear examination in patients with smear-negative
pulmonary TB must be assessed in relation to other strategies
for improving case detection as part of the country’s TB control
efforts; for example, comparisons made with contact investigation
of index patients where the yield may be in the region of 2–5% [9].
In light of above and the evidence generated through this study,
there is need for further evaluation on this research question. End-
of-treatment smear is a low-yield strategy for detection of smear-
positive TB cases, although further studies are needed to
determine its population-level impact and cost, particularly in
relation to other TB control interventions.
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